FLT3 and acute myeloid leukemia: Emavusertib (CA4948) treatment of AML cells exposed to LPS lead to reduced cell viability in FLT3-ITD-positive MOLM-13 cells and enhanced cell viability in FLT3 wild-type ML-2 cells, indicating that a CA4948-induced compensatory IRAK1 activation occurs in FLT3 wild-type cells.